Literature DB >> 28384397

High-Risk Screening for Fabry Disease: Analysis by Tandem Mass Spectrometry of Globotriaosylceramide (Gb3 ) in Urine Collected on Filter Paper.

Christiane Auray-Blais1, Pamela Lavoie1, Michel Boutin1, Mona Abaoui1.   

Abstract

Fabry disease is a complex, panethnic lysosomal storage disorder. It is characterized by the accumulation of glycosphingolipids in tissues, organs, the vascular endothelium, and biological fluids. The reported incidence in different populations is quite variable, ranging from 1:1400 to 1:117,000. Its complexity lies in the marked genotypic and phenotypic heterogeneity. Despite the fact that it is an X-linked disease, more than 600 mutations affect both males and females. In fact, some females may be affected as severely as males. The purpose of this protocol is to focus on the high-risk screening of patients who might have Fabry disease using a simple, rapid, non-invasive high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method for urinary globotriaosylceramide (Gb3 ) analysis. Urine filter paper samples are easily collected at home by patients and sent by regular mail. This method has been successfully used for high-risk screening of patients with ophthalmologic manifestations and in an on-going study for high-risk screening of Fabry disease in patients with chronic kidney diseases. © 2017 by John Wiley & Sons, Inc.
Copyright © 2017 John Wiley & Sons, Inc.

Entities:  

Keywords:  Fabry disease; filter paper sample; globotriaosylceramide (Gb3); high-risk screening; mass spectrometry; urine

Mesh:

Substances:

Year:  2017        PMID: 28384397     DOI: 10.1002/cphg.34

Source DB:  PubMed          Journal:  Curr Protoc Hum Genet        ISSN: 1934-8258


  4 in total

1.  Quantitation of a Urinary Profile of Biomarkers in Gaucher Disease Type 1 Patients Using Tandem Mass Spectrometry.

Authors:  Iskren Menkovic; Michel Boutin; Abdulfatah Alayoubi; Filipa Curado; Peter Bauer; François E Mercier; Christiane Auray-Blais
Journal:  Diagnostics (Basel)       Date:  2022-06-08

2.  Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres.

Authors:  Aizeddin A Mhanni; Christiane Auray-Blais; Michel Boutin; Alie Johnston; Kaye LeMoine; Jill Patterson; Johannes M F G Aerts; Michael L West; Cheryl Rockman-Greenberg
Journal:  Mol Genet Metab Rep       Date:  2020-06-24

3.  Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy.

Authors:  Li Fu; Sylwia Wasiak; Laura M Tsujikawa; Brooke D Rakai; Stephanie C Stotz; Norman C W Wong; Jan O Johansson; Michael Sweeney; Connie M Mohan; Aneal Khan; Ewelina Kulikowski
Journal:  Pharmacol Res Perspect       Date:  2022-06

4.  Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles.

Authors:  Michel Boutin; Pamela Lavoie; Iskren Menkovic; Amanda Toupin; Mona Abaoui; Maha Elidrissi-Elawad; Marie-Françoise Arthus; Carole Fortier; Claudia Ménard; Bruno Maranda; Daniel G Bichet; Christiane Auray-Blais
Journal:  Int J Mol Sci       Date:  2020-08-25       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.